Novai

Biotechnology Research • Reading, England, United Kingdom • 11-20 Employees

Company overview

Headquarters	9 Greyfriars Road, SPACES, Reading, England RG1 1NU, GB
Phone number	+4412457690
Website	novai.co.uk
NAICS	541714
SIC	283
Keywords	Biotechnology, Pharmaceutical, Artificial Intelligence, Glaucoma, Opthalmology, Multiple Sclerosis, Drug Development, Neurodegeneration, Alzheimer'S Disease, Parkinson'S Disease, Biomarker, Age-Related Macular Degeneration, Retinal
Founded	2020
Employees	11-20
Socials

Key Contacts at Novai

Alex Wilson

Director Of Corporate Development & Quality

Paul Stevens

Finance Director

Novai Email Formats

Novai uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@novai.co.uk), used 68.8% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@novai.co.uk	68.8%
{first name}.{last name}	john.doe@novai.co.uk	31.2%

About Novai

Early Detection Prevents Blindness and Disability: Novai is on a mission to combat blindness and disability by pioneering early detection and intervention for eye and brain diseases. At the heart of Novai's innovation is the DARC technology (Detection of Apoptosing Retinal Cells), a novel combination of a proprietary biologic and Artificial Intelligence (AI). The Eye is a Window on to the Brain: DARC stands alone as the sole technology with the ability to observe single cell stress and programmed cell death in the retina. This breakthrough positions DARC as the go-to biomarker to inform clinical decision-making in both ophthalmic and neurodegenerative diseases such as macular degeneration, glaucoma, diabetes, Parkinson's, multiple sclerosis and Alzheimer's. Expertise, Experience and Traction: The company boasts an expert and experienced leadership and advisory team, strong IP rights, and a clear strategy targeting a $40 billion market. Novai has generated £4.2 million from signed sales contracts, contributing to drug development and risk mitigation for Pharma companies using DARC. Series A for Mainstream Adoption: With £4.5 million in investments and £3.3 million in non-dilutive funding secured, Novai is currently on a fundraising drive to raise an additional £10 million towards approval of its use in clinic. DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Novai is headquartered in Reading, UK. For more information, please visit our website www.novai.co.uk

Novai revenue & valuation

Annual revenue	$4,200,000
Revenue per employee	$234,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$13,500,000
Total funding	$1,000,000